A new clinical trial involving triptorelin was registered on August 7, 2026. The study, titled "Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer," is listed as Phase 3. Its current status is not yet recruiting, according to the trial record.
The trial is registered under identifier NCT07751133 and is focused on hormone therapy approaches in patients with metastatic prostate cancer. As a Phase 3 study, it represents a later stage trial in the overall development pathway. No enrollment, results, or outcome data have been posted for this trial at this time.
Triptorelin is an approved compound. This particular study has not begun recruiting participants, so no information about patient enrollment or trial timelines is currently available beyond the registration itself. Further details, including eligibility criteria and study design, are expected to be made available as the trial status updates.
Readers interested in following this trial can refer to the official registration for status changes. For more background on triptorelin, see the compound overview linked with this brief.